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Natural products are an important resource in drug discovery, directly or indirectly delivering numerous
small molecules for potential development as human medicines. Among the many classes of natural
products, alkaloids have a rich history of therapeutic applications. The extensive chemodiversity of
alkaloids found in the marine environment has attracted considerable attention for such uses, while
the scarcity of these natural materials has stimulated efforts towards their total synthesis. This review
focuses on the biological activity of marine alkaloids (covering 2000 to up to 2021) towards Neglected
Tropical Diseases (NTDs) caused by protozoan parasites, and malaria. Chemotherapy represents the
only form of treatment for Chagas disease, human African trypanosomiasis, leishmaniasis and malaria,
but there is currently a restricted arsenal of drugs, which often elicit severe adverse effects, show
variable efficacy or resistance, or are costly. Natural product scaffolds have re-emerged as a focus of
academic drug discovery programmes, offering a different resource to discover new chemical entities
with new modes of action. In this review, the potential of a range of marine alkaloids is analyzed,
accompanied by coverage of synthetic efforts that enable further studies of key antiprotozoal natural
product scaffolds.1. Introduction
2. Protozoal parasite diseases
3. Antiprotozoal marine alkaloids
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Malaria, human African trypanosomiasis (sleeping sickness),
Chagas disease and leishmaniasis are infectious diseases
caused by protozoan parasites, which are transmitted to
humans by insect vectors. Two of these diseases (malaria and
leishmaniasis) occur worldwide,1,2 while the distributions of
Chagas disease and human African trypanosomiasis (HAT) are
mainly conned to Central/South America3 and sub-Saharan
Africa, respectively.4 Over the past decade, another termi-
nology for these diseases has become widely used: malaria is
referred to as a ‘disease of poverty’, while leishmaniasis,
Chagas disease and HAT are described as Neglected Tropical
Diseases (NTDs),5 which refers to diseases of poverty where
both the patients and the diseases themselves have typically
received less funding, and suffered from a lower public health
prole. For NTDs in particular, there is an urgent need for new
therapies to combat the drawbacks associated with existingNat. Prod. Rep.























































































View Article Onlinetreatments, which include adverse side effects (oen leading
to patient compliance issues), limited efficacy or emerging
resistance and, in certain cases, high cost and prolonged
treatment regimens.6–8 These challenges are compounded by
socio-economic consequences for affected nations, which are
oen among the least developed.9 While drug repurposing can
offer one avenue to new treatments,10–12 natural products are
also re-emerging as candidates for the discovery of new anti-
protozoal agents,13 and indeed have a proven track record as
therapeutic agents against protozoal diseases.14,15 Tradition-
ally regarded as non-viable for such purposes due to synthetic
intractability, low natural abundance, polypharmacology, and
inexibility with respect to analogue synthesis, advances in
synthetic organic chemistry offer a realistic means to access
and diversify such scaffolds.16,17 This review focuses on alka-
loids isolated from the marine environment, which have long
been recognised as a low-abundance but high-potential source
of bioactive agents. Following a discussion of the existing stateAndre G. Tempone (BPharm)
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Nat. Prod. Rep.of the art with respect to the diseases and their treatments,
those marine alkaloids that have been evaluated for anti-
protozoal bioactivity in the period 2000–2020 are described,
with an emphasis on the most potent isolates. We then discuss
synthetic approaches to marine alkaloids, emphasising routes
that offer the most efficient access to the important bioactive
alkaloid scaffolds, and those that are well-suited to analogue
design and synthesis.2. Protozoal parasite diseases
Among protozoal parasitic diseases, malaria has received the
most attention due to its widespread nature and impact on
human society. It is caused by ve species of parasites from
the genus Plasmodium, with 219 million cases and 500 000
deaths in 2017 alone (most in sub-Saharan Africa); the species
that results in most fatality is P. falciparum. The main cause of
acute malaria is the erythrocytic stage of the parasite whichPauline Pieper received her PhD
in synthetic organic chemistry
from the University of Neuchâtel
in Switzerland in 2017. She then
joined Prof. Ed Anderson's group
at the University of Oxford,
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View Article Onlinemultiplies rapidly, resulting in up to 200 million cases per
year and causing over 400 000 deaths.18 This stage has
consequently been the main target for clinical intervention
and hence the focus of most drug discovery and development
efforts.
Following the bite of an infected anopheline mosquito, the
sporozoite form of the Plasmodium parasite invades liver cells
(hepatocytes) where it divides, releasing merozoite forms that
infect erythrocytes. The liver stage in P. falciparum infections is
the target for prophylactic drugs, and is an important focus for
P. vivax cure where there is persistent liver infection, including
a dormant hypnozoite form. Maturation of the merozoites into
the sexual gametocyte stage of the parasite in the erythrocytes
offers a further drug target; this is the form that is infective to
the Anopheles mosquito vector where fusion of gametes even-
tually generates further infective sporozoites. Drugs targeting
this stage are ‘altruistic’ drugs – they will not cure the patient
but will prevent transmission. Due to the potential to target
three different stages of the parasite life cycle, research is nowSimon Cro is Professor of
Parasitology at the London
School of Hygiene & Tropical
Medicine. He has worked on the
R & D of anti-infective drugs in
academia, industry and public–
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interests include PK PD rela-
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countries. He is an advisor to UK FCDO and Wellcome Trust
programmes on NTDs. Previously Simon was the R & D Director of
the Drugs for Neglected Diseases Initiative (DNDi), Geneva and
Dean of Faculty at the LSHTM.
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Qúımica, Universidade de São
Paulo (USP) in 1997. He obtained
his Licentiate degree from the
Faculdade de Educação USP in
1999, and his doctorate in
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This journal is © The Royal Society of Chemistry 2021focused on developing combination therapies of drugs with
matched for pharmacokinetic proles;19,20 indeed, the use of
combination therapies for malaria treatment has been a WHO
policy requirement since 2001 as a result of the rapid evolution
of resistant Plasmodium forms using monotherapies. Drug
resistance,21 observed for chloroquine and pyrimethamine as
early as the 1960s, has since been a driver of antimalarial drug
research and development, with major initiatives in the USA
(resulting in meoquine) and China (resulting in artemisinin).
The establishment of the Medicines for Malaria Venture (MMV)
public–private partnership has stimulated the development of
a large portfolio of novel compounds, with over 20 active
projects at stages from discovery to clinical trials.22
Human African trypanosomiasis (HAT), a disease transmitted
by tsetse ies, is caused by trypanosomatid protozoan parasites
that have agella and other unique organelles. Two species cause
this disease: Trypanosoma brucei gambiense (anthroponotic and
distributed in West and Central Africa) and T. b. rhodesiense
(zoonotic and found mainly in Central and East Africa). The
initial acute infection is haemo-lymphatic (stage 1), developing
aer several months into chronic “sleeping sickness” through
invasion of the central nervous system (CNS, stage 2). Over the
past decade the number of cases of HAT has dropped signi-
cantly from over 10 000 to just under 1000 thousand cases per
annum,23 and elimination of HAT is now a realistic target. A
major challenge for drug discovery for HAT is the design of
compounds that can cross the blood–brain barrier to achieve
a sufficiently high concentration in the CNS to kill the parasites.
Until recently, treatment of CNS infections involved the use of
arsenic-based drugs (e.g. melarsoprol). However, in the past
decade the Drugs for Neglected Diseases initiative (DNDi) has
developed fexinidazole, the rst oral treatment for HAT.24
Another potential therapy, acoziborole, is in a clinical trial as
a potential single dose treatment,24 while other lead candidates
have been identied that may offer new opportunities.25Ed Anderson is Professor of
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View Article OnlineChagas disease, which is caused by another trypanosoma-
tid protozoan – Trypanosoma cruzi – is transmitted by tri-
atomine bugs and is both anthroponotic and zoonotic. Upon
infection, the parasite invades many different tissues, dividing
as the intracellular amastigote form in the cell cytoplasm. As
the disease progresses towards the chronic stage, the parasites
appear to go into a latent phase, and for many patients there
can be a 10–30 year period before the potentially fatal chronic
disease appears (with cardiac, neurological and intestinal
complications). An estimated 6–7 million people are infected
with this parasite, with over 10 000 deaths per annum. Drug
development faces the challenges of identifying compounds
that kill both dividing amastigotes and non-dividing trypo-
mastigotes coming from a number of taxonomic units, with
pharmacokinetic properties that ensure distribution to many
tissue types. There are currently two drugs available to treat
Chagas disease: the nitrofuran nifurtimox, and the nitro-
imidazole benznidazole.26,27 Both are oral drugs, but require
long courses of treatment and can have profound side effects
and show variable efficacy. Azoles, as sterol biosynthesis
inhibitors, were also pursued as potential treatments for
several decades, but have shown limited efficacy in clinical
trials. Recently the DNDi has identied the potential of fex-
inidazole, which has recently been evaluated in a Phase II
proof-of-concept study, and has also shown how shorter
courses of benznidazole can be better used to treat chronic
infections.28
Leishmaniasis is a disease complex, with up to 20 different
species of Leishmania that are transmitted by female phle-
botomine sandies. There are several clinically distinct
manifestations, which are broadly classied as either the
potentially fatal visceral leishmaniasis (VL), or the self-curing
but disguring cutaneous leishmaniasis (CL). There are over
100 000 cases of the mainly anthroponotic VL per annum, with
the main foci being in East Africa and the Indian sub-
continent (ISC). In the ISC VL is the subject of an elimina-
tion programme, and there are now less than 5000 cases per
annum. In contrast, some 1–2 million cases per annum of the
mainly zoonotic cutaneous disease (CL) are reported. In
mammalian hosts, the parasites survive and multiply as the
amastigote form within macrophages. The challenge for drug
development has been to identify compounds active against
all or most of the 20 species that cause disease in humans,
with pharmacokinetic properties that enable distribution to
either the liver, spleen, and bone marrow for VL, or the skin
for CL. Complex skin manifestations (such as mucocutaneous
and diffuse cutaneous leishmaniasis) as well as VL/HIV co-
infections add to the challenges for new treatments. Two
therapeutic agents introduced during the past 15 years have
made an impact on visceral leishmaniasis: miltefosine (an
alkylphospholipid administered orally), and a unilamellar
liposomal formulation of the polyketide natural product
amphotericin B (AmBisome®). These two drugs have largely
replaced the traditional pentavalent antimonials for VL,29 but
not for CL where treatment is still dependent on these toxic
heavy metal complexes. Topical formulations have also been
a focus for CL, including several of the aminoglycosideNat. Prod. Rep.paromomycin. New candidates for VL treatment are in devel-
opment:26,27 six clinical and pre-clinical candidates have been
disclosed by the DNDi, with collaboration from two pharma-
ceutical companies (GSK and Novartis).30,31 Some of these
compounds also show potential for CL.323. Antiprotozoal marine alkaloids
Alkaloids comprise an extensive and important group of
secondary metabolites produced by plants, microorganisms,
marine organisms, insects, and animals.33,34 As many alkaloids
likely evolved as chemical defences for marine organisms, the
origin of their bioactivity against human pathogens is
a complex question. Possible factors include conserved
morphology of binding surfaces between proteins of different
sequence and function, genetic homology between different
organisms, and even the biosynthesis of natural products itself,
which requires intermediates to be successfully processed by
a number of enzymes.35One further complication, and potential
benet, is that some natural products have been shown to be
biosynthesized by a co-habiting microorganism. Nonetheless,
the structural diversity of these compounds has provided access
to new areas of chemical space, and the consequent discovery of
activity against human diseases.36,37
While the biological potential of certain alkaloids against
protozoan diseases has been covered previously,38,39 this review
focuses specically on alkaloids isolated from marine organ-
isms andmicroorganisms (Fig. 1–4). In discussing these natural
products, selected semi-synthetic and synthetic derivatives are
also included for relevance of bioactivity (see the ESI† for
tabulation of natural products, marine source, and bioactivity
data, including a ranking of the most active and selective
compounds). For the information of the reader, the terminology
of compound activities is dened in Box 1, and the nature of the
phenotypic assays used for each parasite (and its different
forms where relevant) is outlined in Box 2. Box 3 summarises
some of the most critical accepted criteria for ‘hit’ and ‘lead’
compound identication against P. falciparum, T. cruzi and L.
infantum/L. donovani, as dened by the Japanese Global Health
Innovative Technology, in collaboration with the MMV and the
DNDi.40
The survey of natural products begins with the alkaloid
renieramycin A (1, Fig. 1), which was isolated via bioactivity-
guided fractionation of the lipophilic extract from the
marine sponge Neopetrosia sp. Renieramycin A displayed an
IC50 value of 0.2 mg mL
1 against L. amazonensis promasti-
gotes and a 50% cytotoxicity concentration (CC50) against
mammalian cells of 2.2 mg mL1.43 Araguspongin C (2), iso-
lated from the MeOH extract of the sponge Haliclona exi-
gua,44 is the sole member of a large family of macrocyclic bis-
N,O-acetal containing alkaloids that has been screened for
antiprotozoal activity; it shows in vitro activity against L.
donovani intracellular amastigotes (48% inhibition at 100 mg
mL1) and no mammalian cytotoxicity up to 100 mg mL1.
When administered in L. donovani-infected hamsters, 2
reduced the parasite burden by 39%.45This journal is © The Royal Society of Chemistry 2021
Fig. 1 Natural products and semi-synthetic derivatives 1–27.
Box 1: Terminology of drug activities in experimental
models.
IC50 and IC90 refer to concentrations that inhibit growth of parasites
cultures by 50% and 90%, normally calculated from a dose–response
curve. Some authors use the terms EC50 and EC90, effective concentra-
tions, expressing similar activities.
CC50 and CC90 refer to concentrations that indicate cytotoxic activity
against mammalian cell lines. In this context the selectivity index (SI) is
the ratio of between activity against the mammalian cells (CC50) and the
protozoan parasites (EC50).
ED50 and ED90 refer to the effective doses that reduce parasite load by 50%
and 90% in in vivo studies, normally calculated from dose–response
curves. Reduction in parasitaemia refers only to the blood infection.
Box 2: In vitro phenotypic assays to determine compound
activities.
Data referred to in this review is derived mainly from in vitro assays, which
have been described in detail elsewhere for Plasmodium41 and Trypano-
soma and Leishmania.42
Plasmodium: Most assays are based on intra-erythrocytic cultures of
Plasmodium falciparum strains with compound exposure over 48 hours.
Trypanosoma brucei: Assays are based on cultures of extracellular trypo-
mastigotes of T. brucei spp. with compound exposure over 48 or 72 hours.
Trypanosoma cruzi: Assays are based on either (i) culture of the extracel-
lular epimastigote form, (ii) extracellular trypomastigotes, a non-dividing
stage or (iii) the intracellular amastigote form, grown in a range of
mammalian cell lines for 48 or 72 hours; this is the most relevant assay for
hit identication.
Leishmania: Assays are based on either (i) culture of the extracellular
promastigote form, or (ii) the intracellular amastigote form, grown in
primary isolated macrophages or macrophage cell lines for 48 or 72 hours;
this is the most relevant assay for hit identication. L. donovani/L. infan-
tum are the chosen target species for VL, and either L. major, L. mexicana
and L. braziliensis as the target species for CL.























































































View Article OnlineThe indole alkaloid 8,9-dihydrocoscinamide B (3) was iso-
lated from the marine sponge Conscinoderma sp.46 and, being
a relatively simple target, also accessed by chemical synthesis.47
The synthetic natural product was found to eliminate 97% of
the intracellular amastigotes of L. donovani in vitro at 10 mg
mL1; other synthetic analogues exhibited activity from 59 to
97% inhibition at the same concentration.This journal is © The Royal Society of Chemistry 2021 Nat. Prod. Rep.
Box 3: General hit criteria:
The criteria listed below are as outlined in ref. 40.
 Readily synthesized, not contain reactive/unstable groups in the phar-
macophore, be suited for structural variation; pass drug-like lters (e.g.
pan-assay interference, PAINS).
 SI >10 between mammalian cytotoxicity (CC50) and EC50 (malaria), or
IC50 (CD/VL).
Synthesized in #5 steps with an acceptable yield and solubility.
 No serious IP conicts; preliminary knowledge of the structure–activity
relationship (SAR) is desirable.
General lead criteria:
 High potency (IC50), but not at the expense of physicochemical or drug
metabolism and pharmacokinetic (DMPK) properties.
 Synthesis enables preparation and testing of many analogues in a short
time frame.
 SI >100 between mammalian cytotoxicity (CC50) and EC50 (malaria), or
IC50 (CD/VL); no acute toxicity.
 Desirable physicochemical properties (e.g. solubility >10 mM; log P <5
and ideally <3), suitable DMPK prole, oral efficacy in the relevant disease
model.
Specic criteria: Malaria
Hit: EC50 <1 mM against sensitive and multiple resistant strains of Plas-
modium spp.
Early lead: EC50 <100 nM for sensitive and multidrug-resistant strains of
Plasmodium spp.
 In vivo efficacy criteria: depending on the stage of infection that is tar-
geted; e.g. for the blood stages of infection, 90% of the target pathogen
eradicated in a mouse model at <50 mg per kg, up to four doses over four
days.
Specic criteria: Chagas disease
Hit: IC50 <10 mM against intracellular T. cruzi.
Lead: 80% reduction of parasite burden in organs or tissues in an acute
mouse model, or no parasites detected at the end of treatment and an
increase in lifespan, up to 10 doses at 50 mg per kg delivered orally.
Specic criteria: Visceral leishmaniasis
Hit: IC50 <10 mM against intracellular Leishmania spp.
Lead: >70% reduction in liver parasite burden in a mouse or hamster
model, aer up to 5 doses at 50 mg per kg, delivered orally once or twice
per day.























































































View Article OnlineAmong marine alkaloids, the manzamine natural products
are a particularly important family that has been extensively
studied for their antiprotozoal properties.48,49 For example, the
Indonesian sponge metabolites des-N-methylxestomanzamine
A (4), manzamine A (5), 8-hydroxymanzamine A (6), manz-
amines E (7) and F (8), 12,34-oxamanzamine A (9), 6-deoxy-
manzamine X (10) and manzamine X (11) exhibited in vitro
activity against L. donovani promastigotes with IC50 values of
0.97–35 mg mL1, and CC50 values ranging from 4.7 mg mL
1 to
non-cytotoxic levels (CC50 >4.7 mg mL
1).50 Manzamine A (5)
also displayed in vivo activity against P. berghei at a single dose
(murine model, 100 mmol kg1), reducing the parasite load by
97% at the onset of the parasitaemia.51 5 also prolonged the
survival of treated animals by promoting the production of
specic antibodies (IgG) against the Plasmodium parasite.
Manzamine alkaloids were also isolated from the sponge
Acanthostronglyophora sp., namely manzamine J (12),Nat. Prod. Rep.manzamine A N-oxide (13), ircinal A (14), ircinol A (15), 6-
hydroxymanzamine E (16) and neo-kauluamine (17). These
presented leishmanicidal activity against L. donovani promas-
tigotes with IC50 values of 0.9–25.0 mg mL
1, and CC50 values
ranging from 1.1 mg mL1 to non-cytotoxic concentrations (CC50
>4.7 mg mL1).52 Further studies with the same sponge afforded
manzamine Y (18), 12,28-oxamanzamine A (19), 12,28-oxa-8-
hydroxymanzamine A (20) and 12,28-oxamanzamine E (21),
which led to comparable IC50 values of 1.6–24.0 mg mL
1, and
CC50 values ranging from 1.1 mg mL
1 to non-cytotoxic
concentrations (CC50 >4.7 mg mL
1).53 Semi-synthetic deriva-
tives 8-acetoxymanzamine A (22), 8,12-diacetoxymanzamine A
(23) and 8-methoxymanzamine A (24) exhibited IC50 values
against L. donovani promastigotes of 3.4–16.0 mg mL1, and 30–
1200 ng mL1 against chloroquine-resistant P. falciparum (W2
clone).54 Notably, the relatively low mammalian cytotoxicity of
these compounds (CC50 values of 370 mg mL
1 to non-cytotoxic)
afforded a high selectivity index. In vivo studies with 22 in
Plasmodium-infected mice led to a reduction of parasitaemia of
84% aer 10 days and 48% aer 14 days at 30 mg kg1 (3 oral
doses). Finally, a study of the sponge Amphimedon sp. afforded
the manzamine relative zamamidine C (25), 3,4-dihydro-6-
hydroxy-10,11-epoxymanzamine A (26) and 3,4-dihydromanz-
amine J N-oxide (27), which displayed IC50 values of 0.04–4.40
mg mL1 for T. b. brucei, and 0.58–7.00 mg mL1 for P. falcipa-
rum.49 Although no mammalian cytotoxicity studies were per-
formed, an anticancer assay with KB human epidermoid
carcinoma cells demonstrated IC50 values of 17.7, 7.2, and 6.7
mg mL1 respectively. From these various studies of the manz-
amine family, the most potent activities against L. donovani (1
mg mL1) were obtained for manazmine A (5), manazmine A N-
oxide (13), ircinol A (15) and manzamine Y (18), several of which
have subsequently been accessed by chemical synthesis (vide
infra). It is interesting that ircinol A is both pseudo-enantiomeric
to the majority of the manzamine family, and lacks the typical
carboline sidechain, and yet maintains high levels of anti-
protozoal activity; this may enable simplication of in the
design of manzamine analogues.
In contrast to the structural complexity of the manzamines,
12-deoxyascididemin (28, Fig. 2), ascididemin (29) and eilatin
(30) comprise a small group of relatively simple polycyclic
phenanthrolines isolated from the ascidian Polysyncraton echi-
natum. These alkaloids exhibited potent antitrypanosomal
activity against T. b. brucei with IC50 values of 0.07, 0.03 and 1.30
mM respectively, and CC50 values of 76, 1.4 and 62 mM (corre-
sponding to a promising selectivity index range of 46–99).55
While the parent polyaromatic structures may exhibit undesir-
able physicochemical properties, their structural simplicity
renders them attractive targets for synthesis.
Certain families of marine alkaloids exhibit extensive
bromination, such as the dibromoarene-containing convolut-
amines I (31) and J (32), which were isolated from the hexane
extract of the bryozoan Amathia tortusa.56 These compounds
were evaluated against T. b. brucei, with 31 showing the higher
potency (with an IC50 value of 1.1 mM), but also higher toxicity
against human embryonic kidney cells (32 was non-toxic). The
related bromospiroacetal psammaplysin F (33), isolated fromThis journal is © The Royal Society of Chemistry 2021
Fig. 2 Natural products and synthetic derivatives 28–54.























































































View Article OnlineHyatella sp., showed an IC50 value of 5.6 mM against T. cruzi,57
but a moderate selectivity index. A further isolation from the
dichloromethane/methanol extract of the sponge Pseudocer-
atina sp. afforded 33 along with psammaplysins G (34)58 and H
(35).59 Compound 33 displayed activity against chloroquine-
sensitive and resistant strains of P. falciparum (IC50 values of
1.4 and 0.87 mM, respectively), with a mammalian cytotoxicity
value of CC50 11 mM.58 Psammaplysin H (35) showed the most
potent IC50 value of 0.4 mM against the P. falciparum strain 3D7,
while 34 displayed an IC50 value of 5.2 mM. Importantly, 35 also
displayed no toxicity to mammalian cells to the highest tested
concentration of 40 mM, while 33 and 34 showed mammalian
cytotoxicity below 20 mM.59
Bromopyrrole natural products represent an extensive family
of marine alkaloids that have attracted attention both from
a bioactivity and synthetic perspective. For instance, dibromo-
palauamine (36), longamide B (37), oroidin (38), hymenidin
(39), dispacamide B (40), stevensine (41), spongiacidin B (42),
sceptrin (43), and agelongine (44) were isolated from marine
sponges of the Agelas and Axinella genera;60 evaluation of their
in vitro activity against T. b. rhodesiense and L. donovani revealed
IC50 values of 0.4 and 1.1 mg mL
1 respectively for 36, while 37
displayed IC50 values of 1.5 and 3.8 mg mL
1 respectively,
although both compounds possessed some toxicity againstThis journal is © The Royal Society of Chemistry 2021mammalian cells. The other active compounds in this collec-
tion displayed antiprotozoal activities against T. b. rhodesiense
with IC50 values between 9.7 and 78 mM, and against L. donovani
with IC50 values between 16 and 77 mM. Compounds 42, 40 and
36 proved the most active compounds against P. falciparum
(with IC50 values of 1.1, 1.3 and 1.5 mM respectively); the other
active compounds afforded values between 3.9 and 12.5 mM.60
The anti-plasmodial activity of oroidin (38) potentially arises
from inhibition of the P. falciparum enoyl-ACP reductase
(PfFabI) enzyme (IC50 0.30 mg mL
1 ¼ 0.77 mM).61
Numerous indole alkaloids have been isolated from marine
sources. Bioactivity-guided fractionation of the EtOAc extract of
the marine bacterium Bacillus pumilus, collected from the black
coral Antipathes sp., led to isolation of 3-hydroxyacetylindole
(45), acetyl-b-oxotryptamine (46), and 3-formylindole (47). These
compounds inhibited T. cruzi amastigotes with IC50 values of
19.4–26.9 mM, but showed no activity against P. falciparum or L.
donovani. 46 and 47 showed cytotoxicity for African green
monkey kidney cells (CC50 values of 66 and 87 mM,
respectively).62
The polycyclic indoles fascaplysin (48) and homofascaplysin
(49) were obtained from the dichloromethane/MeOH extract of
the sponge Hyrtios cf. erecta, and were found to exhibit
impressive levels of antiprotozoal activity.63 48 showed in vitroNat. Prod. Rep.























































































View Article Onlineactivity against T. b. rhodesiense (IC50 0.17 mg mL
1) and against
the K1 and NF54 strains of P. falciparum (IC50 50 and 34 ng
mL1 respectively), while 49 exhibited IC50 values of 14 and 24
ng mL1 respectively against the latter. With CC50 values of 1.1
and 2.5 mg mL1 respectively, both compounds displayed
promising selectivity indices; together with their structural
accessibility, this has rendered them popular targets for total
synthesis (vide infra). This is similarly the case for the indolo-
carbazole alkaloid staurosporine (50), isolated from the sponge
associated actinomycetes Streptomyces sp.; this compound
showed activity against L. major promastigotes (IC50 of 5.3 mM),
and T. b. brucei (IC50 of 20 nM, with a CC50 value of 1.3 mM
against 293T kidney epithelial cells; SI of 65).64
The rather simpler indole alkaloid tryptophol (51), obtained
from sponge species Spongia sp. and Ircinia sp., exhibited
activity against L. donovani amastigotes (IC50 9.6 mg mL
1), T.
cruzi amastigotes (IC50 49 mg mL
1) and T. b. rhodesiense try-
pomastigotes (IC50 of 5.9 mg mL
1), with CC50 values of 63 mg
mL1.65 The indole spermidine alkaloids didemnidines A (52)
and B (53), isolated from the ascidian Didemnum sp., were also
prepared by chemical synthesis; these compounds (and
synthetic intermediates en route) exhibited no activity against L.Fig. 3 Natural products and synthetic derivatives 55–88.
Nat. Prod. Rep.donovani amastigotes, but were moderately active against T.
cruzi amastigotes (IC50 28–130 mM) and T. b. rhodesiense trypo-
mastigotes (IC50 9.9–59.0 mM).66 Evaluation against the K1 strain
of P. falciparum afforded IC50 values between 8.4 and 41 mM, but
mammalian cytotoxicity was signicant, with CC50 values
around 25 mM.
Moving away from indole derivatives, diazepinomicin (54) is
an interesting dibenzodiazepine obtained from the Micro-
monospora sp. RV115 strain isolated from the sponge Aplysina
aerophoba.67 When tested against T. b. brucei trypomastigotes,
54 displayed an IC50 value of 13.6 mM, with no toxicity to human
kidney cells HK-2 at 25 mM. The natural product was found to
inhibit the T. b. brucei protease rhodesain.
Quaternized aromatic azacycles feature prominently in
marine alkaloids, and oen exhibit useful antiprotozoal
activity. A study with Paenibacillus sp. strain DE2SH, isolated
from mangrove rhizosphere soils in Ghanaian wetlands, affor-
ded the bis-imidazolium alkaloid paenidigyamycin A (55,
Fig. 3).68 This compound displayed IC50 values of 0.75 mM (L.
major promastigotes), 7.0 mM (L. donovani promastigotes), 0.78
mM (T. b. brucei trypomastigotes), and 9.1 mM (P. falciparum).
Natural and synthetic pyridinium ions have also been studiedThis journal is © The Royal Society of Chemistry 2021























































































View Article Onlinefor antiprotozoal properties. The arctic sponge Haliclona viscosa
has afforded a number of alkylpyridinium alkaloids such as
viscosamine (56);69 in the course of synthetic studies towards 56,
a number of 2-tridecylpyridinium alkaloids were prepared and
evaluated for antiprotozoal activity alongside 56, including
natural product mimics such as 57 and 58.70 These compounds
showed antitrypanosomal potential against T. brucei (IC50 of the
synthetic analogues 0.014 to 16 mM), and antileishmanial
potential against L. major promastigotes (IC50 0.032–50 mM) and
L. mexicana amastigotes (IC50 0.19–50 mM). Potent antimalarial
activity was also observed, with IC50 values of 0.053–7.5 mM
against P. falciparum. The mammalian cytotoxicity against
HEK293 cells resulted in CC50 values of 11–204 mM, suggesting
promising selectivity indexes, especially for T. brucei.
An extensive range of pyrimidine and guanidine alkaloids
have been isolated from marine sources. For example, the
sponge Monanchora arbuscula yielded batzelladine A (59), nor-
batzelladine A (60), dinorbatzelladine A (61), dinordehy-
drobatzelladine B (62), dihomodehydrobatzelladine C (63),
clathriadic acid (64), ptilomycalin A (65) batzelladine L (66) and
norbatzelladine L (67), which were tested for antiplasmodial
activity, with many exhibiting high potency.71 Ptilomycalin A
(65) was found to be the most active against P. falciparum, with
an IC50 value of 0.1 mM, while norbatzelladines A and L (60 and
67) and batzelladines A and L (59 and 66) showed activities in
the range of 0.2–0.4 mM; 62–64 displayed IC50 values of 0.8–4.5
mM. Batzelladine L (66), norbatzelladine L (67), batzelladine F
(68), batzelladine D (69) and monalidine A (70) afforded IC50
values of 2–64 mM for T. cruzi trypomastigotes, and 2–4 mM for L.
infantum promastigotes;72 the lack of a second tricyclic guani-
dinium ion in batzelladine D (69) appears highly detrimental to
T. cruzi activity, but makes little difference for L. infantum. In
terms of mechanism of action, batzelladine L and
norbatzelladine L (66 and 67) caused an increase in the
permeability of the Leishmania plasma membrane, and depo-
larization of the mitochondrial membrane. 66 in particular
induced a signicant increase in the production of reactive
oxygen species (ROS), a potential pathway to cell death.72 The
mammalian cytotoxicity against monkey kidney cells LLC-MK2
ranged from 22–130 mM. The dichloromethane/MeOH extract of
the marine sponge Monanchora unguilata afforded further
batzelladine-like alkaloids that were tested for in vitro antima-
larial activity;73 the pentacyclic spirocycles ptilomycalins E (71),
F (72), the mixture of ptilomycalin G and H (73 and 74), cram-
bescidin 800 (75) and fromiamycalin (76) all showed nanomolar
potency against P. falciparum (IC50 0.23–0.52 mM), but also
elevated mammalian cytotoxicity, with CC50 values of 0.8–1.6
mM. Unguilicin A (77), an acyclic guanidine alkaloid, exhibited
an IC50 value of 12.9 mM, but again showed high toxicity to
mammalian KB cells. Based on these results, a number of
simplied synthetic analogues were prepared as tetra-
uoroborate salts, and tested against T. cruzi and L. infantum.74
Representative examples include the tricyclic batzelladine gua-
nidinium ion mimics 78 and 79 and the spiroaminal guanidi-
nium 80, a mimic of ptilomycalin A. IC50 values below 10 mM
were shown against T. cruzi trypomastigotes and L. infantum
amastigotes in a number of cases; importantly, someThis journal is © The Royal Society of Chemistry 2021compounds showed no mammalian cytotoxicity to the highest
tested concentration of 150 mM. As with batzelladine L, 79
caused an increase in the permeability of the Leishmania plasma
membrane and the levels of ROS, along with depolarization of
the mitochondrial membrane. These results suggest there are
further opportunities for the development of synthetic batzel-
ladines/ptilomycalins.
A number of sulfur-containing alkaloids have been found to
display highly promising anti-protozoal bioactivities. For
example, screening of lissoclinotoxin E (81) (along with various
other compounds from marine sources) for activity against T.
cruzi, L. donovani and T. b. brucei revealed activity against all
three parasites with IC50 values of 0.7–4.4 mM.57 Thiapla-
kortones A–D (82–85), isolated from the sponge Plakortis lita,
exhibited sub-micromolar activity against chloroquine-sensitive
and chloroquine-resistant lines of P. falciparum, with IC50
values of 51–650 nM, accompanied by reduced cytotoxicity
against the HEK293 cell line,75 resulting in exceptional selec-
tivity indices from >62 to >285; saturation of the sulfone-
containing ring (as in thiaplakortone A) resulted in a tenfold
increase in bioactivity. Being relatively simple from a structural
perspective, this family thus represents an attractive synthetic
target, and indeed thiaplakortone A and a synthetic analogue 86
were found to present micromolar activity against T. b. brucei
and T. cruzi.57
8-Oxo-tryptamine (87), and a mixture of (E)- and (Z)-bromo-
20-demethyl-30-N-methylaplysinopsin (88), were isolated from
the dichloromethane/methanol extract of the sponge Fascaply-
sinopsis reticulate;76 both exhibited activity against P. falciparum
with IC50 values around 8 mg mL
1. Hyrtiodoline A (89),
a further indole alkaloid isolated from a marine sponge of the
Hyrtios genus, displayed in vitro antitrypanosomal properties
against T. b. brucei (IC50 of 15.3 mM), with no cytotoxicity against
J774.1 macrophages (CC50 >200 mM).77
Several polyazacyclic marine natural products have been
shown to exhibit promising anti-protozoal properties. For
example, caulamidines A (90, Fig. 4) and B (91), obtained from
the bryozoan species Caulibugula intermis, showed activity
against chloroquine-sensitive and chloroquine-resistant strains
of P. falciparum (IC50 8.3–12.9 mM) with low mammalian cyto-
toxicity to NCI-60 cells at 40 mM.78 The two enantiomers of
eudistidine C (92) were isolated through bioactivity-guided
fractionation of an ascidian Eudistoma sp. extract, and dis-
played micromolar antimalarial activity against P. falciparum
(IC50 2.8 and 4.2 mM).79 The related alkaloid eudistidine A (93)
showed similar antiplasmodial potential (IC50 1.4 mM),80 while
synthesis of eudistidine C analogues such as 94 resulted in
activity against chloroquine-sensitive and chloroquine-resistant
strains of P. falciparum with IC50 values as low as 1.1 mM.79 The
brevity of this synthetic route (vide infra) certainly opens up
further opportunities for exploration of this family.
Various exocyclic guanidine and aminopyrimidine alkaloids
have been studied with respect to their antiprotozoal properties.
Extraction of the sponge Biemna laboutei led to the isolation of
several such compounds, including netamine K (95) and mir-
abilin A (96). Both showed promising antimalarial activity with
IC50 values of 2.4 and 21.0 mM respectively.81 Three relatedNat. Prod. Rep.
Fig. 4 Natural products and synthetic derivatives 93–122.























































































View Article Onlineguanidines (mirabilin B 97, and hydroxyptilocaulins 98 and 99)
were obtained from the bioactive EtOH extract of the marine
spongeMonanchora unguifera; 97 was found to be active against
L. donovani promastigotes with (IC50 17.0 mg mL
1), while
a mixture of 98 and 99 displayed activity against P. falciparum
(IC50 3.8 mg mL
1).82 Both 97 and the mixture of 98 and 99 were
inactive against fourteen cancer cell lines, suggesting low
mammalian cytotoxicity. Further studies on B. laboutei afforded
other bioactive tricyclic guanidines, including netamines O
(100), P (101) and Q (102) which displayed in vitro antimalarial
activity (IC50 of 8.3–33.0 mM).83 The bioactivities of this family
show high sensitivity to the nature of the various sidechains,
and extent of oxidation of the pyrimidine core.
Nortopsentin A (103) is a structurally distinct bis-(indolyl)
imidazole alkaloid found in the sponge Sponhosorites sp., which
displayed antimalarial activity against chloroquine- resistant P.
falciparum with an IC50 value of 0.4 mM, resulting in a selectivity
index of 14;84 other marine-derived alkaloids studied in this
work showed tenfold reduced activity. A number of synthetic
approaches to the structurally accessible nortopsentin family
have been described, but their wider antiprotozoal prole has
yet to be evaluated.85
The ingamine alkaloid family consists of two macrocyclic
amines built around a bis-piperidine core. Ingamine A (104),
(22S)-hydroxyingamine A (105) and dihydroingenamine D (106)
were isolated from the marine sponge Petrosid Ng5 Sp5; these
compounds displayed highly promising activity againstNat. Prod. Rep.chloroquine-sensitive (IC50 72–220 ng mL
1) and chloroquine-
resistant (IC50 57–140 ng mL
1) P. falciparum, and showed no
cytotoxicity to mammalian cells up to 10 mg mL1.86 The
dichloromethane/methanol extract of the marine sponge Neo-
petrosia proxima afforded the related bis-piperidine alkaloid neo-
petrosiamine A (107), which also displayed promising bioactivity
against P. falciparum (IC50 2.3 mM).87 For both of these families,
extensive study of antiprotozoal function remains to be explored.
Fractionation of the butanone extract of the marine actino-
mycete Marinactinospora thermotolerans led to isolation of the
alkaloids marinacarbolines A–D (108–111), as well as indo-
lactams 13-N-demethyl-methylpendolmycin (112) and methyl-
pendolmycin-14-O-a-glucoside (113).88 In vitro antimalarial
evaluation of these compounds afforded IC50 values of 1.9–39
mM for both drug-sensitive and resistant strains of P. falciparum,
albeit accompanied by signicant cytotoxicity. Meridianin A
(114), isolated from Psammopemma sp., and synthetic analogues
4-methoxymeridianin A (115) and meridoquin (116), were eval-
uated with regard to their antimalarial potential, affording IC50
values of 12–200 mM; only the natural compound 114 was found
to be cytotoxic,89 while the diethylamino group in 116 resulted
in a signicant loss of activity compared to the free NH2. Mer-
idianins C (117) and G (118), isolated from the tunicate Aplidium
meridianum,90 exhibited improved in vitro antimalarial proper-
ties (IC50 9.7–14.4 mM), and showed no cytotoxicity against
several mammalian and human cell lines up to 25 mM.91This journal is © The Royal Society of Chemistry 2021
Scheme 2 Silver-promoted imine/alkyne cyclization route to fasca-
plysin (48) (Waldmann and co-workers).97























































































View Article OnlineMonamphilectine A (119) is a unique b-lactam isonitrile
alkaloid isolated from themarine spongeHymeniacidon sp. This
compound displayed potent activity against chloroquine-
resistant P. falciparum (IC50 40 nM).92 Finally, lepadins D–F
(120–122) were isolated from a marine sponge of the genus
Didemnum;93 activity was displayed against T. cruzi amastigotes
(IC50 2.2–37 mg mL
1), T. b. brucei (IC50 0.2–5.6 mg mL
1), and
against two strains of P. falciparum (IC50 0.2–6.1 and 0.4–10 mg
mL1). Showing low mammalian cytotoxicity (CC50 values from
16 to >30 mg mL1), the lepadins have accordingly stimulated
much synthetic interest (vide infra). Esterication of the
secondary alcohol on the piperidine ring appears important for
bioactivity – lepadin D being tenfold less active than lepadins E
and F.
In summary, the marine environment is without doubt a rich
source of molecularly diverse alkaloids, many displaying useful
levels of antiprotozoal behavior. Of course, these compounds
are not pre-optimized for use against protozoal parasitic
diseases, and their exploitation therefore relies on the devel-
opment of robust and exible chemical syntheses, such that
structure activity relationships and analogue synthesis can be
achieved in a cost- and time-effective manner.
4. Synthetic approaches to
antiprotozoal marine natural products
This section discusses chemical synthesis approaches to anti-
protozoal natural products. In the context of this review, an
exhaustive coverage of the natural product syntheses achieved is
not possible; instead, representative examples from important
family classes are included, with a focus on routes that are
potentially scalable, and/or amenable to analogue synthesis,
and/or exhibit particular efficiency in accessing challenging
synthetic targets.
4.1. Indole alkaloids
Indole alkaloids comprise one of the largest class of sponge-
derived metabolites exhibiting antiprotozoal activity. b-
Carboline-type ring systems are common motifs among marineScheme 1 Cyclization/dehydrogenation/N-ring closure cascade
sequence to fascaplysin (48) (Bharate and co-workers).94
This journal is © The Royal Society of Chemistry 2021indole alkaloids, as typied by fascaplysin (48, Scheme 1),
originally isolated from the marine sponge Fascapfysinopsis
Bergquist sp.63,95 Displaying potent activity against the K1 and
NF54 strains of P. falciparum (IC50 50 and 34 ng mL
1 respec-
tively), several attractive approaches have been described to
access this natural product. For example, Bharate and co-
workers used a cascade process to form the b-carboline ring
system,94 building on existing methodology for b-carboline
synthesis.96 This involved condensation of tryptamine (123)
with aromatic glyoxal 124 to give imine 125, which underwent
Pictet–Spengler cyclization at C2 of the indole, followed by Pd/C-
mediated dehydrogenation/aromatization in acetic acid to yield
b-carboline 127. On heating to 220 C for 20 min, cyclization of
127 produced fascaplysin in 68% overall yield. This concise
strategy should be amenable to gram-scale production of fas-
caplysin and analogues, albeit the thermal cyclization was only
performed on 50 mg scale in this work.
Another appealing route to fascaplysin was reported by
Waldmann and co-workers, who used a silver(I)-promotedScheme 3 Oxidative condensation/Pictet–Spengler cyclization route
to fascaplysin (48) (Zhu and co-workers).98
Nat. Prod. Rep.
Scheme 4 Synthesis of nortopsentins B (139) and D (140) (Miyake and
co-workers).99























































































View Article Onlinecondensation/cyclization of aldehydes and anilines (Scheme
2).97 The silver catalyst promotes cyclization of imine 130
(derived from starting materials 128 and 129) onto the indolyl
alkyne, leading to a pyridinium ion which, aer proto-
demetallation, underwent a second cyclisation by the pendent
malonate nucleophile to form 132. A nal re-aromatization step
delivered fascaplysin C (134) in 61% yield, which was converted
to fascaplysin (48) in two further steps.
A third approach, disclosed by the Zhu group, again features
a cascade coupling protocol for the synthesis of the b-carboline
ring system from simple starting materials (Scheme 3).98 This
route starts with iodination of the haloacetophenone (135), which
underwent a Kornblum oxidation with DMSO to give a phenyl-
glyoxal intermediate (136). In situ condensation with tryptamine
(137), followed by Pictet–Spengler cyclization and oxidation,
afforded b-carbolines (138) in an impressive 95/96% yield. These
compounds could be converted to fascaplysin in a further two
steps.
The nortopsentins are a class of imidazole-linked bis-indoles
isolated from Spongosorites ruetzleri.100 Their potent and diverseScheme 5 Synthesis of ircinal A (14), iricinol A (15) and manzamine A (5
Nat. Prod. Rep.antiprotozoal activities have made them very attractive
compounds as candidates for new drug design, in particular
with respect to their antiplasmodial activity (IC50 0.4 mM against
P. falciparum).84 Miyake and co-workers developed an efficient
synthesis to access nortopsentins B (139, Scheme 4) and D (140)
via oxotryptamine 141, which was obtained by a direct hydro-
genation of acyl cyanide 142 over Pd/C.99 A Markwald imidazole
synthesis between 141 and 3-cyanoindole 144 delivered nor-
topsentin D (140), while reaction of 141 with 6-bromo-3-
cyanoindole 145, obtained by bromination of 144 meta to the
indole nitrogen, gave nortopsentin B (139).
Themanzamine and ircinal alkaloids comprise a structurally
complex set of indole natural products isolated from Haliclona
sp.102 and several sponges Acanthostrongylophora sp.50–53,103 Their
challenging architectures might not at rst sight seem suited to
the preparation of analogues, albeit semi-synthetic modica-
tions have been described.104 Nonetheless, a number of
synthetic approaches have been reported;101,105–108 the recent
total synthesis of ircinal A (14, Scheme 5), ircinol A (15) and
manzamine A (5) by Dixon et al.101 is not only the shortest route,
but could enable the installation of a variety of heteroaromatics
in place of the b-carboline ring system, as well as modication
of the macrocyclic alkene region, due to the late-stage intro-
duction of these motifs. These are particularly important targets
since, as noted above, manazmine A and ircinol A display potent
activity against L. donovani (1 mg mL1).
From a synthetic perspective, this impressive route features
the elegant use of two nitro functionalities to mediate C–C bond
formation, and a late-stage ring closing metathesis to assemble
the macrocyclic alkene. The synthesis began with the addition
of the potassium enolate derived from 5,8-fused ring lactam 146
(itself obtained in ve steps from commercially available (R)-5-
(hydroxymethyl)pyrrolidin-2-one) to nitroalkene 147, to give
adduct 148. Having enabled this initial challenging conjugate
addition, the nitro group played a second role in a nitro-
Mannich reaction with the imine derived from hex-5-en-1-) (Dixon and co-workers).101
This journal is © The Royal Society of Chemistry 2021
Scheme 6 Synthesis of staurosporinone (161) (Gaunt and co-workers).113
Scheme 7 Total synthesis of (+)-mirabilin B (97) (Snider and co-
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View Article Onlineamine and formaldehyde, in situ cyclization delivering lactam
149. Having served its purpose, this nitro group was cleaved
under reductive conditions, while a second was introduced on
the acetal sidechain (150). Under Lewis acid promotion, this
enabled a further nitro-Mannich ring closure to tetracycle 151.
In this case, the nitro group was oxidized to the corre-
sponding ketone via a McMurray–Nef reaction, stereoselective
addition of butenylmagnesium bromide to which afforded
tertiary alcohol 152. Aer temporary alcohol silylation, kinetic
enol triate formation was followed by a moderately Z-selective
macro-RCM to give enol triate 153. This compound served
asthe direct precursor to ircinal A (14) by palladium-catalyzed
formylation, and to ircinol A (15) by palladium-catalyzed car-
bonylative esterication, followed by reduction. Finally, manz-
amine A (5) itself was constructed from 153 by Stille coupling
with the requisite heteroaryl stannane (18 steps in total, longest
linear sequence).
The indolocarbazole staurosporine family of natural prod-
ucts, isolated from sponge-associated actinomyces64 and
Nocardiopsis sp. K-252,79,109 also present a signicant synthetic
challenge – especially in terms of analogue preparation.110–112
While staurosporine (50, Scheme 6) has been shown to exhibit
potent activity against T. b. brucei (IC50 22 nM), its aglycon
staurosporinone (161) has not been tested, and analogues
remain elusive. The Gaunt group devised a highly appealing
and concise approach that centres on four arene C–H activa-
tions – a scalable and modular strategy that could enable the
preparation of staurosporinone analogues.113 This synthesis
begins with the readily available dibenzyl p-toluidine (154),
which underwent a copper-catalyzed C–H arylation with
diphenyliododium triate to give 155 aer a protecting group
switch. The amide group was now able to direct a second,meta-
selective C–H arylation, affording triphenyl 157. The nitrogen
substituent required for the second staurosporine indole was
then introduced by nitration at the remaining ortho position
relative to the amide, setting the stage for heterocycle forma-
tion. This began with copper-catalyzed C–H amidation to
afford 158, and aer two steps involving oxidation andThis journal is © The Royal Society of Chemistry 2021reductive amination on the aryl methyl group, amine 159 was
subjected to a palladium-catalyzed carbonylative C–H lactam-
ization, delivering the fully- substituted arene core 160. Nitro
reduction using triethylphosphite triggered a nal arene ami-
nation reaction via a formal nitrene insertion into the proximal
aryl C–H bond. The synthesis of staurosporinone (161) was
completed by benzyl cleavage using BCl3/n-Bu4NI. Many of the
intermediates in this route were accessed on multigram scale,
and the modular and regioselective manner in which the
substituents were introduced suggests this approach could
hold promise for the wider exploration of staurosporinone
biology.workers).
Nat. Prod. Rep.























































































View Article Online4.2. Guanidine alkaloids
4.2.1. Exocyclic guanidines. Marine sponges are a prolic
source of polycyclic guanidine-containing compounds,
including the tricyclic ptilocaulin, mirabilin and netamine
heterocycles.72,82 In what constitutes the only total synthesis to
date of mirabilin B (31, Scheme 7), Snider and co-workers
developed an approach based on the condensation of guani-
dine with an indenone (162).114 This indenone was prepared in
six steps, beginning with an asymmetric organocatalytic
Michael addition of b-ketoester 163 to enal 164, promoted by
the diarylprolinol catalyst 165. Following acid-promoted cyclo-
condensation, the enantioenriched enone 166 was isolated in
respectable yield. A four step sequence involving 1,2-addition of
methyllithium and allylic oxygen transposition delivered alde-
hyde 167 aer oxidative cleavage of the alkene sidechain, which
underwent anintramolecular aldol/dehydration sequence to
give indenone 162, the key intermediate for condensation with
guanidine. In the event, this reaction proceeded neat at elevated
temperature, with an in situ oxidation affording mirabilin B (31)
in moderate yield (39%) along with cyclic guanidinium ion 168.
More appealingly, treatment of 162 with guanidine in MeOH,
followed by oxidation of intermediate 7-epi-neoptilocaulin 169
with MnO2, gave mirabilin B exclusively, in high yield (80%).
Eudistidines A (93, Scheme 8) and C (92) feature a poly-
azaphenanthrene core with aminoimidazole or anisole side-
chains, respectively. Isolated from the marine ascidian
Eudistoma sp. by Schnermann, Gustafson and co-workers,79,80
these natural products display low micromolar activity against
P. falciparum, and have been accessed by a concise synthetic
route that enabled the testing of a number of natural product
analogues.79 This route commenced with 2-nitroacetophenone
170, which underwent condensation with DMF dimethyl acetal
to give enaminone 171.115 Reaction with guanidine hydrochlo-
ride followed by nitro group reduction affordedScheme 8 Total synthesis of eudisitidines A (93) and C (92) (Schner-
mann, Gustafson and co-workers).79,80
Nat. Prod. Rep.aminopyrimidine 172. This compound was converted to
eudistidine A (93) by condensation/cyclization with aryl glyoxal
173, then in situ iodine-mediated oxidation – overall a four step
sequence from commercial starting materials. The hemiaminal
in eudistidine A represents a convenient site for introduction of
other sidechains, including the eudistidine C aminoimidazole
ring, which was incorporated by simple stirring of eudistidine A
with amine 174 at room temperature. This high-yielding
sequence appears well-suited to a broader survey of eudisti-
dine biology.
4.2.2. Endocyclic guanidines. The antiprotozoal alkaloid
()-batzelladine D (69, Scheme 9), isolated from the Caribbean
sponge Batzella sp., is a member of another family of bioactive
polycyclic guanidine-containing marine alkaloids.72 The tricy-
clic guanidine core is highly conserved throughout this family,
while modications of the ester side chain elicit different bio-
logical activity, which can extend to micromolar or even sub-
micromolar levels against P. falciparum and T. cruzi. Elegant
routes have been developed to access a number of members of
the batzelladine family;116–120 Evans and co-workers recently re-
ported the most concise, enantioselective total synthesis to date
of ()-batzelladine D (69) via a 14 step sequence, in an
impressive 10% overall yield.121 The synthetic strategy is based
on a combination of a stereospecic rhodium catalyzed allylic
amination, and a diastereoselective free-radical cyclization. The
route begins with the preparation of enantiomerically enriched
3,4-dihydropyrimidin-2(1H)-one 175 in two steps from
commercially available methyl 3,3-dimethoxypropionate 176,
via acid-catalyzed Biginelli condensation followed by a regiose-
lective sulfonylation with (1S)-(+)-camphorsulfonyl chlorideScheme 9 Stereospecific rhodium catalyzed allylic amination/dia-
stereoselective free-radical cyclization in the total synthesis of
()-batzelladine D (69) (Evans and co-workers).121
This journal is © The Royal Society of Chemistry 2021
Scheme 11 Total synthesis of longamide B (37) (Trost and Dong).125























































































View Article Online(diastereomers separated by column chromatography). Then,
rhodium-catalyzed allylic amination of 175 with cyclic
carbonate 177, which was prepared in three steps from the C2-
symmetrical bis-epoxide 178, furnished 179 in 84% yield with
high diastereoselectivity (dr >30 : 1). A ve step sequence of
functional group manipulations afforded alkyl iodide 180,
which underwent radical cyclization with tributyltin hydride
under triethylborane initiation to give the pyrrolo-[1,2-f]-
pyrimidine 181 in 80% yield, and 19 : 1 dr ()-batzelladine D
itself (69) was obtained in a further four steps (54% yield).
While the batzelladine alkaloid family themselves represent
challenging synthetic targets, they have also inspired the
exploration of simplied natural product analogues that
maintain bioactivity. One example is the pentacyclic ptilomy-
calin A analogue 80 (Scheme 10), which displayed useful levels
of activity against L. infantum (IC50 8 mM) and low toxicity (SI
>19).74 Due to its inherent symmetry, this compound can be
prepared in just four steps from v-valerolactone 182 by ring-
opening with methylene triphenylphosphorane, and silylation
to afford phosphorane 183.122 A double Wittig reaction with
succinaldehyde gave bis-enone 184, treatment of which with
guanidine effected a tandem Michael addition; acidic workup
cleaved the silyl ethers, triggering spiroaminal formation onto
the intermediate diketone. This concise synthesis clearly
demonstrates the potential of natural products to inspire the
development of new and synthetically tractable antiprotozoal
agents.4.3. Bromopyrrole alkaloids
A variety of bromopyrrole-containing sponge metabolites have
been tested for their antiprotozoal properties. Among the
simplest, and therefore attractive for further development, is
longamide B (37, Scheme 11, originally isolated from Agelas
dispar),23 which showed particularly notable activity against T. b.
rhodesiense and L. donovani.60 Trost and Dong reported
a concise route to access longamide B that centred on an
asymmetric palladium-catalyzed addition of A pyrrole nucleo-
phile to a racemic vinyl aziridine (a dynamic kinetic asymmetric
transformation, DYKAT).125 In the context of the natural product
synthesis, reaction of racemic vinyl aziridine 185 (prepared inScheme 10 Two-directional synthesis of ptilomycalin analogue 80
(Murphy and co-workers).122
This journal is © The Royal Society of Chemistry 2021two steps from 1-amino-3-buten-2-ol) with commercial bromo-
pyrrole 186 in the presence of a chiral palladium catalyst gave
the product pyrrolopyrazinone 187 in72% yield and 95% ee. A
three step sequence involving alkene hydroboration/oxidation,
dimethoxybenzyl cleavage, and pyrrole bromination afforded
188, which could be converted to longamide B (37) by oxidation
with TEMPO/bis- acetoxyiodobenzene (BAIB) in high yield. A
further publication from the Trost group126 demonstrated that
a wide range of pyrrole- or indolopyrazinone derivatives should
be accessible using this approach, including other natural
products.
The biosynthesis of sceptrin (43, Scheme 12), a cyclobutane
bis-imidazole natural product isolated from Agelas sceptrum127
likely involves [2+2] dimerization of two simpler amino-
imidazole metabolites, triggered by single electron transfer
oxidation.123,124 Notably, while sceptrin itself has been shown
to exhibit notable antiprotozoal activity against T. b. rhode-
siense and P. falciparum, equivalent proling of its relatives
ageliferin and massadine has yet to be carried out. From
a synthetic perspective, access to all three of these natural
products has been established by the Chen group;123 for the
purposes of this review, only the route to sceptrin will be
described.124 This route commences with (D)-glutamic acid
(189), which was converted to lactone 190 by anchimeric lac-
tonization. Reduction of the acid, followed by lactone reduc-
tion and elimination of the resulting hemiacetal, gave enol
ether 191. This electron-rich alkene enabled installation of the
alkenylimidazole 192 (prepared in four steps from benzylox-
ymethyl imidazole) via selenoetherication; oxidative elimi-
nation of the intermediate selenide afforded dihydrofuran
193. Staudinger reduction of the azide in 193 to the imino-
phosphine was followed by a tethered photoredox formal [2+2]
cycloaddition, which efficiently constructed the sceptrin
cyclobutane (194), albeit as a mixture of diastereomers (1.8 : 1)
at the indicated ring carbon. Next, transacetalization afforded
the cyclobutane 195. At this point, the synthesis suffers from
a lengthy endgame sequence involving careful functional
group manipulations; most interesting is that the imino-
phosphine is maintained until the penultimate step of theNat. Prod. Rep.
Scheme 12 Synthesis of sceptrin (43) (Chen and co-workers).123,124























































































View Article Onlinesynthesis. While this route has not yet been applied to
analogue synthesis, the efficiency of the tethered photo-
chemical [2+2] suggests simple sceptrin analogues could likely
be prepared using this approach.4.4. Thiazine alkaloids
The benzothiazine alkaloids thiaplakortones A–D (82–85) were
isolated from the Australian sponge Plakortis lita as a result of
a high-throughput screen for antimalarial compounds.75 The
family exhibit sub-micromolar activity against P. falciparum, but
are also effective against T. cruzi and T. b. brucei. Pouwer and co-
workers developed a simple and efficient synthesis of thiapla-
kortone A (82, Scheme 13),128 and several thiaplakortone
analogues.129 This began with tryptamine derivative 197, which
was readily obtained in ve steps from 4-hydroxyindole (198,
including only two chromatographic separations). In initial
work, this scalable precursor was derivatized by selectiveScheme 13 Synthesis of thiaplakortone A (82) (Pouwer and co-
workers).128
Nat. Prod. Rep.methylation on the pyrrole nitrogen, and/or N-methylation of
the Boc-protected amine sidechain. Benzyl deprotection fol-
lowed by oxidation with Fremy's salt gave an unstable quinone
intermediate 199, which was directly subjected to a double
conjugate addition/oxidation sequence upon treatment with 2-
aminoethanesulnic acid, to yield dihydrothiazone dioxide 200
as a separable mixture of regioisomers. Finally, oxidation of the
dihydrothiazone and deprotection of the carbamate group
afforded thiaplakortone A (82). This efficient and scalable
synthesis enabled a further SAR study via N-acylations and
pyrrole alkylation, which improved the pharmacodynamic
properties of the molecule, albeit oral bioavailability remains an
identied challenge.98,1294.5. Miscellaneous alkaloids
Ascididemin (29, Scheme 14), a pentacyclic tripyridyl frame-
work isolated from Polysyncraton echinatum, displays nano-
molar activity against T. b. brucei.130 With a relatively simple
framework, this natural product has been prepared on
a number of occasions.131–138 However, from a developmental
perspective, syntheses that are truly scalable or amenable to
analogue synthesis are more challenging. Two approaches are
particularly notable in this context; the rst is the seminal
route from Bracher131 which has been developed for analogue
synthesis by Delfourne and co-workers due to its convenient
and convergent nature.139 This chemistry begins with
a conjugate addition of 2-amino-acetophenone 201 to 5,8-
quinolone 202, presumably promoted by Ce(III) chelation by
the quinolone nitrogen and proximal carbonyl. Treatment of
this adduct (203) under acidic conditions effected cyclization/
aerobic oxidation to 204. Condensation with DMFDMA gave
enamine 205, which was nally converted to ascididemin (29)
on reaction with ammonium chloride. In addition to some
direct modications of the natural product, this route was
applied to the synthesis of six ascididemin analogues for
anticancer proling, and would clearly translate to an anti-
protozoal context.139This journal is © The Royal Society of Chemistry 2021
Scheme 15 Synthesis of ascididemin (29) (Peterson and co-
workers).137
140
Scheme 14 Synthesis of ascididemin (29) (Bracher, Delfourne and co-
workers).131,139























































































View Article OnlineThe second approach, disclosed by Petersen and co-
workers,137 features a complementary cross-coupling strategy to
assemble the bipyridyl segment of the natural product (Scheme
15). This route begins with Knoevenagel condensation of
malononitrile with 2-uoroacetophenone (206), then for-
mylation with DMFDMA. Treatment of this product (207) with
HCl effects direct chloropyridine formation (208) in an
impressive 81% yield over the three steps. This sets the stage for
Negishi coupling of pyridylzinc 209, forming bypyridine 210 in
high yield. Finally, an anionic cyclization cascade is initiated on
treatment with sodium hydride, where deprotonation of the 3-
methylpyridine motif triggers cyclization onto the proximal
nitrile, and then SNAr cyclization onto the uoroarene. The
resultant pentacycle 211 was directly oxidized (O2) to ascidide-
min (29). Comprising just six steps, the modular nature of this
synthesis should be readily adapted for analogue exploration.
The lepadin family of decahydroquinoline alkaloids are
important targets due to low or sub-microgram mL1 activity
against Trypanosoma and Plasmodium parasites. However, the
enantioselective synthesis of these structures, with appropriate
sidechain installation, has proven challenging. An attractive
and potentially scalable approach that is amenable to analogue
synthesis was reported by the Charette group, in their synthesis
of lepadin B (212, Scheme 16).140 This work begins with pyri-
dine, dearomatization of which by N-alkylation with Tf2O-
activated N-benzoyl-O-methyl-L-valinol 213, followed by addi-
tion of MeMgBr, afforded dihydropyridine 214. This underwent
a diastereoselective Diels–Alder reaction to azabicyclo[2.2.2]
octane 215, which was advanced to enantiopure amidoalkene
216. This set up an elegant ring-opening/ring-closing metath-
esis reaction which proceeded on gram scale in a matter of
minutes. While a number of steps were needed to advance
product 217 to lepadin B, the basis of this route offers a viable
entry to this natural product family.
Finally, the cyclic tridecylpyridinium alkaloid viscosamine
56 (and non-natural analogues) have been prepared byThis journal is © The Royal Society of Chemistry 2021Rodenko, de Koning and co-workers using a straightforward
iterative strategy (Scheme 17).70 This begins with pyridine 218,
which is converted to iodide 219 aer pyridine protection as a p-
methoxybenzylpyridinium ion. Reaction of 219 with 218, then
iodination of the resident alcohol and a further alkylation with
218, delivers trimer 220. The PMB group is cleaved by reaction
with excess pyridine, then iodination and cyclization under
high dilution (0.0017M) affords viscosamine 56. Exhibiting sub-
micromolar levels of activity against Leishmania, Trypanosoma
and Plasmodium parasites, these polar compounds present
interesting opportunities for further development.4.6. Opportunities for chemistry
While natural product synthesis can frequently be stimulated by
the complexity and challenge of a target molecule, the syntheses
described above offer genuine prospects for the study and
development of natural product inspired antiprotozoal ‘hit’Scheme 16 Synthesis of lepadin B (212) (Charette and co-workers).
Nat. Prod. Rep.
Scheme 17 Synthesis of viscosamine (56) (Rodenko, de Koning and
co-workers).70























































































View Article Onlinecompounds. For example, the Rodenko and de Koning
synthesis of viscosamine and its synthetic analogues,70 which
display potent and selective activity against all three parasite
genera discussed in this review, can be accessed on multi-
100 mg scale; activity against L. donovani or L. infantum para-
sites has yet to be evaluated. The same is true of the thiapla-
kortone family,128,129 where synthesis on multi-100 mg scale has
been achieved – these compounds and analogues displaying
promising activity and selectivity against P. falciparum and T.
cruzi. The relatively simple structures of fascaplysin and nor-
topsentin, which exhibit low micromolar antimalarial activity
and should both be accessible on gram scale using the chem-
istry described, offer similar potential for development.
More challenging natural products are gradually becoming
potential candidates for study, but only where genuinely effi-
cient and modular syntheses have been reported. Probably the
best example of this is the Dixon route to the manzamine/
ircinol scaffold,101 a modular approach which comprises 18
steps in the longest linear sequence, many of which have been
carried out on multigram scales. The natural diversity of the
manzamine family, matched by the range of biological prop-
erties, suggests that this class could be ripe for exploration. For
other natural products, challenge still remains – for example,
the lepadins are attractive as anti-trypanosomal compounds,
but reported syntheses have not yet demonstrated true scal-
ability, while the complex batzelladine family can now be
prepared on multi-10 mg scales, enabling a wider exploration of
antiprotozoal properties,74 but toxicity issues are yet to be
overcome. With respect to antileishmanial studies, many alka-
loid families have not even been evaluated, which further
complicates target selection from a chemical perspective.
5. Conclusions
The marine environment offers a wide chemodiversity of
natural products, and hence great potential for drug discovery.
Many of these compounds likely evolved as chemical defences
for the producing organism, but whatever the basis of the anti-
protozoal activities and selectivities of marine alkaloids, it is
clear that many of these compounds could indeed serve as an
inspiration for the development of novel antiprotozoal chemical
entities. For this to become reality, the development of efficientNat. Prod. Rep.total syntheses must underpin the production of new deriva-
tives; recent developments as highlighted in this review show
that this goal is within reach. In spite of this potential, few
marine alkaloids have yet been tested in animal models of
infection, where optimization to improve solubility, stability,
pharmacokinetic properties, potency and selectivity become key
issues. The elimination of poor-quality compounds, known as
pan-assay interference compounds (PAINs), is a further essen-
tial consideration to improve the success of drug discovery
programmes into malaria and protozoan NTDs. Of the many
natural products discussed in this review, a number exhibit
activity against more than one parasite type, but the majority
remain to be screened against different parasite targets,
offering further scope for the discovery of useful bioactive
agents. Despite these challenges, the allure of these Nature-
optimized leads remains undiminished, and with improved
access to both the natural alkaloids and non-natural derivatives,
the likelihood of success in the development of natural product-
inspired therapies is ever increasing.6. Conflicts of interest
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39 M. Álvarez-Bardón, Y. Pérez-Pertejo, C. Ordóñez,
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É. G. Pinto, T. A. da Costa-Silva, E. Hajdu, A. G. Ferreira,
R. A. Santos, P. J. Murphy, R. J. Andersen, A. G. Tempone
and R. G. S. Berlinck, J. Nat. Prod., 2015, 78, 1101–1112.
73 P.-E. Campos, J.-L. Wolfender, E. F. Queiroz, L. Marcourt,
A. Al-Mourabit, M. Frederich, A. Bordignon, N. De Voogd,
B. Illien and A. Gauvin-Bialecki, J. Nat. Prod., 2017, 80,
1404–1410.
74 L. F. Martins, J. T. Mesquita, E. G. Pinto, T. A. Costa-Silva,
S. E. T. Borborema, A. J. Galisteo Junior, B. J. Neves,
C. H. Andrade, Z. A. Shuhaib, E. L. Bennett, G. P. Black,
P. M. Harper, D. M. Evans, H. S. Fituri, J. P. Leyland,
C. Martin, T. D. Roberts, A. J. Thornhill, S. A. Vale,
A. Howard-Jones, D. A. Thomas, H. L. Williams,
L. E. Overman, R. G. S. Berlinck, P. J. Murphy and
A. G. Tempone, J. Nat. Prod., 2016, 79, 2202–2210.
75 R. A. Davis, S. Duffy, S. Fletcher, V. M. Avery and R. J. Quinn,
J. Org. Chem., 2013, 78, 9608–9613.
76 P.-E. Campos, E. Pichon, C. Moriou, P. Clerc, R. Trépos,
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